漿細胞樣泌尿道上皮癌：台中榮民總醫院的經驗
陳思如, 楊晨洸
台中榮民總醫院泌尿外科部
Plasmacytoid Urothelial Carcinoma : TCVGH experience
Szu-ju, Chen, Cheng-kuang, Yang
Division of Urology, Department of Surgery, Taichung Veterans General Hospital, Taichung,Taiwan
Purpose:
Plasmacytoid urothelial carcinoma is a rare bladder cancer histological variant with rare data on outcomes and prognostic factors.
We analyzed our institutional plasmacytoid bladder cancer cases and treatment experience with this histology to see response to systemic therapies , definitive surgery and survival results.
Materials and Methods:
We conducted a retrospective chart review of consecutive patients with plasmacytoid who was seen in our institution (2017– 2022). Baseline characteristics, clinicopathologic and treatment data were analyzed.
Results:
Twenty-one patients with plasmacytoid urothelial histology were identified; 67% of those with plasmacytoid presented with initial cT3/4 and 39% clinical node positive stage. Plasmacytoid histology was associated with lower median overall survival and higher recurrent and metastatic proportion.
Conclusion:
Plasmacytoid urothelial carcinoma frequently presented with advanced stage at diagnosis and extirpative surgery, poor pathologic response to neoadjuvant chemotherapy, and inferior outcomes, when compared to conventional urothelial. Prospective trials evaluating upfront cystectomy versus preoperative chemotherapy and/or novel treatments should be considered.